Health & Fitness
Health and Fitness
Health and Fitness
Fri, February 27, 2009
Thu, February 26, 2009 HemoBioTech Announces Publication of a Guest Editorial and Two Review Articles on Blood Substitutes by Dr. Jan Simoni " Co-Inve
DALLAS--([ BUSINESS WIRE ])--HemoBioTech (OTCBB:HMBT) ([ www.hemobiotech.com ]) announced today the publication of a guest editorial and two review articles by Dr. Jan Simoni on blood substitutes in the Journal of Artificial Organs (Vol. 33, No. 2, 2009). The editorial entitled: "Artificial Oxygen Carriers: Scientific and Biotechnological Points of View," examines the need for blood substitutes and evaluates the status of blood substitutes under development worldwide. The review articles provide a detailed analysis of the problems associated with the development of blood substitutes and describe the strategies on how to create safe and effective products, including HemoTech that could be the first viable substitute for human red blood cells. Dr. Simoni, who co-invented HemoTech, is a Research Professor of Surgery at Texas Tech University and Acting Vice President of R&D and Production for HemoBioTech.
The articles by Dr. Simoni particularly focus on the intrinsic toxicity of hemoglobin. Such toxicity has plagued all first generation hemoglobin-based blood substitute products. HemoTech overcomes the intrinsic toxicity of hemoglobin by modification with ATP, Adenosine and GSH. HemoBioTech has the exclusive worldwide license for commercial development of HemoTech from Texas Tech University.
On April 29-30, 2008, the FDA held a public workshop on safety of hemoglobin based oxygen carriers. It was concluded that first generation products indeed had toxicity and efficacy problems and that there was a need for new generation products. The use of Adenosine and GSH to modify hemoglobin was presented as a viable strategy for a new generation blood substitute. The method of modification of hemoglobin with Adenosine and GSH is the strategy used in HemoTech and is patented in 21 countries.
"We are very pleased that Dr. Simoni is recognized as a leader in the field of hemoglobin-based blood substitutes as reflected in the guest editorial and review articles published in Artificial Organs," said Dr. Arthur P. Bollon, Ph.D., Chairman and CEO of HemoBioTech. "We are focusing on HemoTech to satisfy a growing need for a viable substitute for human red blood cells, whether as a global alternative to HIV contaminated blood which causes about 10% of new HIV AIDS cases globally or for trauma or other medical applications."
About HemoBioTech, Inc.
HemoBioTech is engaged in the commercial development of HemoTech, a novel human blood substitute technology developed by Texas Tech University Health Sciences Center scientists, Drs. Mario Feola and Jan Simoni, and exclusively licensed from Texas Tech University System. HemoTech is composed of bovine hemoglobin that is chemically modified with ATP, Adenosine and GSH. HemoTech not only can carry oxygen in the blood, but can also induce erythropoiesis (red blood cell production). The Company believes that HemoTech, due to its novel structure, may possess properties that diminish the intrinsic toxicities that have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S. HemoTech is being subjected to further studies and testing to confirm and expand on these studies. At a recent meeting in April, 2008 by the U.S. Food and Drug Administration (FDA) for blood substitutes, the FDA indicated the need for a new generation of hemoglobin based blood substitutes and the Adenosine-GSH approach of HemoTech was cited. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other conditions. Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information contact, Dr. Arthur Bollon at 972-455-8955, [ arthurb@flash.net ] or visit our website at: [ http://www.hemobiotech.com ].
Safe Harbor Statement
Except for historical information, the matters discussed in this news release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech's Annual Report on Form 10-K for the year ending December 31, 2007, as amended, and HemoBioTech's other reports filed with the Securities and Exchange Commission.
